|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.339 EUR | +0.21% |
|
+0.67% | +16.11% |
| 13/01 | Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec | RE |
| 08/01 | Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies | MT |
Company Valuation: Evotec SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,950 | 7,444 | 2,696 | 3,765 | 1,453 | 1,122 | 1,122 | - |
| Change | - | 50.39% | -63.78% | 39.63% | -61.41% | -22.8% | 0% | - |
| Enterprise Value (EV) 1 | 4,949 | 7,099 | 2,485 | 3,787 | 1,669 | 1,197 | 1,233 | 1,195 |
| Change | - | 43.43% | -65% | 52.43% | -55.93% | -28.3% | 3.03% | -3.1% |
| P/E ratio | 757x | 32.7x | -15.4x | -45.3x | -7.38x | -17.1x | -46.4x | 45.1x |
| PBR | 6.86x | 5.44x | 2.27x | 3.37x | 6.89x | 1.28x | 1.33x | 1.31x |
| PEG | - | 0x | 0x | 0.9x | -0x | 0.3x | 0.7x | -0x |
| Capitalization / Revenue | 9.88x | 12x | 3.59x | 4.82x | 1.82x | 1.44x | 1.34x | 1.21x |
| EV / Revenue | 9.88x | 11.5x | 3.31x | 4.85x | 2.09x | 1.53x | 1.47x | 1.28x |
| EV / EBITDA | 46.4x | 66.2x | 24.4x | 57.1x | 74x | 36.9x | 14.2x | 8.13x |
| EV / EBIT | 102x | 173x | 119x | -142x | -11.7x | -18.1x | -67.1x | 25.1x |
| EV / FCF | -91.1x | 2,155x | 114x | -21.4x | -16.8x | -8.61x | -86.2x | 35.1x |
| FCF Yield | -1.1% | 0.05% | 0.88% | -4.67% | -5.95% | -11.6% | -1.16% | 2.85% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.04 | 1.3 | -0.99 | -0.47 | -1.11 | -0.3705 | -0.1363 | 0.1402 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 500.9 | 618 | 751.4 | 781.4 | 797 | 781.2 | 839.7 | 929.7 |
| EBITDA 1 | 106.6 | 107.3 | 101.7 | 66.35 | 22.56 | 32.4 | 86.72 | 146.9 |
| EBIT 1 | 48.52 | 41 | 20.85 | -26.63 | -142.5 | -66.18 | -18.36 | 47.57 |
| Net income 1 | 6.252 | 215.5 | -175.7 | -83.91 | -196.1 | -77.33 | -28.16 | 40.3 |
| Net Debt 1 | -0.669 | -345.3 | -211.8 | 22.09 | 216 | 74.9 | 111.1 | 72.85 |
| Reference price 2 | 30.280 | 42.500 | 15.260 | 21.280 | 8.195 | 6.326 | 6.326 | 6.326 |
| Nbr of stocks (in thousands) | 1,63,476 | 1,75,162 | 1,76,703 | 1,76,936 | 1,77,303 | 1,77,323 | 1,77,323 | - |
| Announcement Date | 25/03/21 | 12/04/22 | 12/05/23 | 24/04/24 | 17/04/25 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.07x | 1.53x | 36.94x | -.--% | 130.22Cr | |
| 39.23x | 5.69x | 19.06x | 0.88% | 4.94TCr | |
| 33.98x | 3.36x | 14.37x | -.--% | 4.11TCr | |
| 103.5x | 6.63x | 66.63x | -.--% | 3.74TCr | |
| 55.58x | 11.4x | 31.68x | 0.35% | 3.14TCr | |
| -22.06x | 6405.73x | -20.93x | -.--% | 2.38TCr | |
| 41.75x | 6.77x | 30.78x | -.--% | 1.74TCr | |
| 28.03x | 2.24x | 10.03x | 0.87% | 1.49TCr | |
| 27.09x | 2.1x | 10.74x | -.--% | 1.39TCr | |
| Average | 32.22x | 716.16x | 22.14x | 0.23% | 2.56TCr | |
| Weighted average by Cap. | 43.03x | 667.20x | 23.43x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- EVT Stock
- Valuation Evotec SE
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition